Table 4.
Composite endpoint analysis
CLASI-50 | SRI-4 | BICLA | ||||
Placebo | RSLV-132 | Placebo | RSLV-132 | Placebo | RSLV-132 | |
All participants (N=65) |
25% | 36% | 35% | 28% | 20% | 26% |
Baseline CLASI ≥21 (N=30) |
25% | 39% | 8% | 39% | 8% | 28% |
Baseline SLEDAI ≥9 (N=22) |
11% | 31% | 44% | 62% | 11% | 23% |
BICLA, British Isles Lupus Assessment Group-based Composite Lupus Assessment; CLASI, Cutaneous Lupus Erythematosus Disease Area and Severity Index; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SRI-4, SLE Responder Index 4.